Which has stronger valuation and earnings, URGN or LNTH?

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Urogen Pharma $109.79M 21.30 -$153.49M -$1.98 N/A Lantheus $1.56B 4.23 $233.56M $4.14 24.38

Is URGN or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Urogen Pharma -51.73% N/A -43.79% Lantheus 17.69% 28.10% 14.35%

Does the media favor URGN or LNTH?

In the previous week, Urogen Pharma had 2 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Urogen Pharma and 12 mentions for Lantheus. Lantheus' average media sentiment score of 1.23 beat Urogen Pharma's score of 0.89 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 7 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BLTE or URGN?

In the previous week, Belite Bio had 7 more articles in the media than Urogen Pharma. MarketBeat recorded 21 mentions for Belite Bio and 14 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.89 beat Belite Bio's score of 0.72 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor URGN or AMRX?

In the previous week, Urogen Pharma and Urogen Pharma both had 14 articles in the media. Urogen Pharma's average media sentiment score of 0.89 beat Amneal Pharmaceuticals' score of 0.67 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor URGN or EWTX?

In the previous week, Urogen Pharma and Urogen Pharma both had 14 articles in the media. Urogen Pharma's average media sentiment score of 0.89 beat Edgewise Therapeutics' score of 0.13 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Edgewise Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is URGN or MANE more profitable?

Veradermics has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Company Net Margins Return on Equity Return on Assets Urogen Pharma -51.73% N/A -43.79% Veradermics N/A N/A N/A

Does the media favor URGN or MANE?

In the previous week, Urogen Pharma had 11 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Urogen Pharma and 3 mentions for Veradermics. Urogen Pharma's average media sentiment score of 0.89 beat Veradermics' score of 0.66 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Urogen Pharma (URGN) Competitors

$47.85 -0.27 (-0.57%)

As of 01:34 PM Eastern

Compare

URGN vs. LNTH, BLTE, AMRX, EWTX, and MANE

Should you buy Urogen Pharma stock or one of its competitors? Urogen Pharma's main competitors and comparable companies include Lantheus (LNTH), Belite Bio (BLTE), Amneal Pharmaceuticals (AMRX), Edgewise Therapeutics (EWTX), and Veradermics (MANE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Urogen Pharma compare to Lantheus?

Urogen Pharma (NASDAQ:URGN) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Urogen Pharma presently has a consensus price target of $48.78, suggesting a potential upside of 1.96%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.11%. Given Lantheus' higher probable upside, analysts plainly believe Lantheus is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Lantheus	0 Sell rating(s)	9 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

Urogen Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to Urogen Pharma's net margin of -51.73%. Lantheus' return on equity of 28.10% beat Urogen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Lantheus	17.69%	28.10%	14.35%

Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	21.30	-$153.49M	-$1.98	N/A
Lantheus	$1.56B	4.23	$233.56M	$4.14	24.38

In the previous week, Urogen Pharma had 2 more articles in the media than Lantheus. MarketBeat recorded 14 mentions for Urogen Pharma and 12 mentions for Lantheus. Lantheus' average media sentiment score of 1.23 beat Urogen Pharma's score of 0.89 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	7 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Lantheus beats Urogen Pharma on 10 of the 17 factors compared between the two stocks.

How does Urogen Pharma compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Urogen Pharma (NASDAQ:URGN) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Belite Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Belite Bio has higher earnings, but lower revenue than Urogen Pharma. Belite Bio is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Urogen Pharma	$109.79M	21.30	-$153.49M	-$1.98	N/A

In the previous week, Belite Bio had 7 more articles in the media than Urogen Pharma. MarketBeat recorded 21 mentions for Belite Bio and 14 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.89 beat Belite Bio's score of 0.72 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio currently has a consensus target price of $205.80, suggesting a potential upside of 28.10%. Urogen Pharma has a consensus target price of $48.78, suggesting a potential upside of 1.96%. Given Belite Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Belite Bio is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Belite Bio has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Urogen Pharma	-51.73%	N/A	-43.79%

Summary

Urogen Pharma beats Belite Bio on 8 of the 15 factors compared between the two stocks.

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Urogen Pharma (NASDAQ:URGN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Amneal Pharmaceuticals has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	21.30	-$153.49M	-$1.98	N/A
Amneal Pharmaceuticals	$3.12B	1.81	$72.06M	$0.49	36.11

Urogen Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, suggesting that its share price is 27% more volatile than the broader market.

91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Urogen Pharma currently has a consensus price target of $48.78, suggesting a potential upside of 1.96%. Amneal Pharmaceuticals has a consensus price target of $17.67, suggesting a potential downside of 0.16%. Given Urogen Pharma's higher probable upside, equities analysts clearly believe Urogen Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00

In the previous week, Urogen Pharma and Urogen Pharma both had 14 articles in the media. Urogen Pharma's average media sentiment score of 0.89 beat Amneal Pharmaceuticals' score of 0.67 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amneal Pharmaceuticals beats Urogen Pharma on 8 of the 15 factors compared between the two stocks.

How does Urogen Pharma compare to Edgewise Therapeutics?

Urogen Pharma (NASDAQ:URGN) and Edgewise Therapeutics (NASDAQ:EWTX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Urogen Pharma presently has a consensus target price of $48.78, suggesting a potential upside of 1.96%. Edgewise Therapeutics has a consensus target price of $49.08, suggesting a potential upside of 12.98%. Given Edgewise Therapeutics' higher probable upside, analysts plainly believe Edgewise Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Urogen Pharma has higher revenue and earnings than Edgewise Therapeutics. Urogen Pharma is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	21.30	-$153.49M	-$1.98	N/A
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%. Urogen Pharma's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Edgewise Therapeutics	N/A	-39.01%	-36.96%

Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Edgewise Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

91.3% of Urogen Pharma shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Comparatively, 21.3% of Edgewise Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Urogen Pharma and Urogen Pharma both had 14 articles in the media. Urogen Pharma's average media sentiment score of 0.89 beat Edgewise Therapeutics' score of 0.13 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Edgewise Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Urogen Pharma and Edgewise Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Urogen Pharma compare to Veradermics?

Urogen Pharma (NASDAQ:URGN) and Veradermics (NYSE:MANE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Urogen Pharma currently has a consensus price target of $48.78, suggesting a potential upside of 1.96%. Veradermics has a consensus price target of $153.00, suggesting a potential upside of 35.39%. Given Veradermics' higher probable upside, analysts plainly believe Veradermics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Veradermics has lower revenue, but higher earnings than Urogen Pharma. Veradermics is trading at a lower price-to-earnings ratio than Urogen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Urogen Pharma	$109.79M	21.30	-$153.49M	-$1.98	N/A
Veradermics	N/A	N/A	-$70M	-$1.32	N/A

Veradermics has a net margin of 0.00% compared to Urogen Pharma's net margin of -51.73%.

Company	Net Margins	Return on Equity	Return on Assets
Urogen Pharma	-51.73%	N/A	-43.79%
Veradermics	N/A	N/A	N/A

In the previous week, Urogen Pharma had 11 more articles in the media than Veradermics. MarketBeat recorded 14 mentions for Urogen Pharma and 3 mentions for Veradermics. Urogen Pharma's average media sentiment score of 0.89 beat Veradermics' score of 0.66 indicating that Urogen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Urogen Pharma	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.3% of Urogen Pharma shares are owned by institutional investors. 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Urogen Pharma beats Veradermics on 9 of the 14 factors compared between the two stocks.

Get Urogen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

URGN vs. The Competition

Export

Metric	Urogen Pharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.33B	$11.72B	$6.98B	$13.02B
Dividend Yield	N/A	2.70%	2.58%	10.72%
P/E Ratio	-24.11	781.44	269.27	25.25
Price / Sales	21.30	748.15	597.31	101.05
Price / Cash	N/A	67.45	70.53	50.75
Price / Book	-17.65	10.77	13.07	6.33
Net Income	-$153.49M	$2.78B	$3.45B	$347.81M
7 Day Performance	1.87%	-0.17%	0.74%	0.90%
1 Month Performance	22.07%	0.00%	1.40%	0.89%
1 Year Performance	138.24%	161.17%	67.03%	20.36%

Urogen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
URGN Urogen Pharma	2.5499 of 5 stars	$47.85 -0.6%	$48.78 +1.9%	+139.3%	$2.34B	$109.79M	N/A	200
LNTH Lantheus	3.5361 of 5 stars	$101.50 +0.4%	$108.11 +6.5%	+87.7%	$6.58B	$1.54B	24.46	1,193	Positive News
BLTE Belite Bio	3.9502 of 5 stars	$158.50 +0.8%	$203.00 +28.1%	+132.3%	$6.30B	N/A	N/A	10	Trending News Analyst Forecast
AMRX Amneal Pharmaceuticals	3.3188 of 5 stars	$18.46 -0.1%	$17.67 -4.3%	+83.7%	$5.90B	$3.02B	21.49	8,500	Positive News Analyst Downgrade Insider Trade
EWTX Edgewise Therapeutics	2.3106 of 5 stars	$44.99 +0.6%	$48.75 +8.4%	+214.5%	$4.81B	N/A	N/A	60	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:URGN) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Urogen Pharma (URGN) Competitors

URGN vs. LNTH, BLTE, AMRX, EWTX, and MANE

How does Urogen Pharma compare to Lantheus?

Summary

How does Urogen Pharma compare to Belite Bio?

Summary

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Summary

How does Urogen Pharma compare to Edgewise Therapeutics?

Summary

How does Urogen Pharma compare to Veradermics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Urogen Pharma (URGN) Competitors

URGN vs. LNTH, BLTE, AMRX, EWTX, and MANE

How does Urogen Pharma compare to Lantheus?

Do analysts rate URGN or LNTH?

Which has more volatility & risk, URGN or LNTH?

Is URGN or LNTH more profitable?

Which has stronger valuation and earnings, URGN or LNTH?

Does the media favor URGN or LNTH?

Do institutionals and insiders have more ownership in URGN or LNTH?

Summary

How does Urogen Pharma compare to Belite Bio?

Which has more volatility and risk, BLTE or URGN?

Which has stronger valuation & earnings, BLTE or URGN?

Does the media prefer BLTE or URGN?

Do analysts prefer BLTE or URGN?

Do insiders and institutionals hold more shares of BLTE or URGN?

Is BLTE or URGN more profitable?

Summary

How does Urogen Pharma compare to Amneal Pharmaceuticals?

Which has preferable earnings & valuation, URGN or AMRX?

Which has more volatility and risk, URGN or AMRX?

Do insiders and institutionals hold more shares of URGN or AMRX?

Is URGN or AMRX more profitable?

Do analysts rate URGN or AMRX?

Does the media favor URGN or AMRX?

Summary

How does Urogen Pharma compare to Edgewise Therapeutics?

Do analysts rate URGN or EWTX?

Which has stronger valuation & earnings, URGN or EWTX?

Is URGN or EWTX more profitable?

Which has more risk & volatility, URGN or EWTX?

Do insiders & institutionals hold more shares of URGN or EWTX?

Does the media favor URGN or EWTX?

Summary

How does Urogen Pharma compare to Veradermics?

Do analysts prefer URGN or MANE?

Which has preferable earnings and valuation, URGN or MANE?

Is URGN or MANE more profitable?

Does the media favor URGN or MANE?

Do institutionals and insiders hold more shares of URGN or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN vs. The Competition

Urogen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools